Cadrenal Therapeutics, Inc.
CVKD
$12.32
-$0.1618-1.30%
NASDAQ
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 119.10% | 100.23% | 203.78% | 86.49% | 54.52% |
| Depreciation & Amortization | -20.00% | 816.67% | -33.33% | -33.33% | -16.67% |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 51.39% | 123.74% | 238.53% | 115.30% | 140.36% |
| Operating Income | -51.39% | -123.74% | -238.53% | -115.30% | -140.36% |
| Income Before Tax | -53.25% | -131.19% | -265.99% | -132.30% | -138.58% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -53.25% | -131.19% | -265.99% | -132.30% | -138.58% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -53.25% | -131.19% | -265.99% | -132.30% | -138.58% |
| EBIT | -51.39% | -123.74% | -238.53% | -115.30% | -140.36% |
| EBITDA | -51.41% | -123.50% | -238.66% | -115.38% | -140.45% |
| EPS Basic | 16.62% | -33.80% | -138.77% | -115.98% | -74.71% |
| Normalized Basic EPS | 16.63% | -33.80% | -138.78% | -115.99% | -74.72% |
| EPS Diluted | 16.62% | -33.80% | -138.77% | -115.98% | -74.71% |
| Normalized Diluted EPS | 16.63% | -33.80% | -138.78% | -115.99% | -74.72% |
| Average Basic Shares Outstanding | 83.81% | 72.80% | 53.29% | 7.56% | 36.56% |
| Average Diluted Shares Outstanding | 83.81% | 72.80% | 53.29% | 7.56% | 36.56% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |